15
Cat No. | Product Name | Synonyms | Targets |
---|---|---|---|
T36841 | IPI-9119 | Fatty Acid Synthase | |
IPI-9119 is an orally active, selective and irreversible FASN inhibitor (IC50 = 0.3 nM). | |||
T9005 | VPC-80051 racemate | Others | |
VPC-80051 is the first small molecule inhibitor of hnRNP A1 splicing activity by using a computer-aided drug discovery approach. | |||
T78989 | BET-IN-16 | Epigenetic Reader Domain | |
BET-IN-16 (Comp I), a bromodomain and extra-terminal (BET) inhibitor, demonstrates anticancer activity by impeding the growth of prostate cancer cells. It exhibits potent inhibitory effects with half-maximal inhibitory c... | |||
T78837 | CP-07 | CDK | |
CP-07 is a selective and effective PROTAC CDK9 degrader (DC50: 43 nM), demonstrating inhibition of 22RV1 cell proliferation (IC50: 62 nM) and colony formation by attenuating levels of Mcl-1 and c-Myc. Additionally, CP-07... | |||
T61327 | BRD4 Inhibitor-15 | ||
BRD4 Inhibitor-15 (compound 13) is a highly potent and specific inhibitor of BRD4, effectively inhibiting it with an IC50 of 18 nM. By regulating the Bcl-2/Bax proteins and activating the caspase-3 signaling pathway, BRD... | |||
T63109 | Y08284 | ||
Y08284 is a selective, potent, orally active inhibitor of CBP bromodomain (IC50: 4.21 nM). y08284 inhibits the proliferation of the prostate cancer cell lines LNCaP, C4-2B and 22Rv1 and has anti-tumour effects. | |||
T13552 | ARD-266 | Others | |
ARD-266 is a highly potent and VHL E3 ligase-based androgen receptor (AR) PROTAC degrader. ARD-266 effectively induces the degradation of AR protein in AR-positive LNCaP, VCaP, and 22Rv1 prostate cancer cell lines (DC50s... | |||
T15205 | EL-102 | EL102 | Microtubule Associated , HIF |
EL-102 is a HIF1α inhibitor with anticancer activity that inhibits microtubule protein polymerization and can be used to study prostate cancer. | |||
T13958 | VHL Ligand 8 | Others | |
VHL Ligand 8, a VHL ligand essential for synthesizing ARD-266, acts as a highly potent VHL E3 ligase-based androgen receptor (AR) PROTAC degrader. It efficiently facilitates the degradation of AR protein in AR-positive p... | |||
T78945 | WCA-814 | Androgen Receptor | |
WCA-814, an androgen receptor (AR) antagonist-Hsp90 inhibitor conjugate, induces degradation of both full-length and AR-V7, exhibiting cytotoxic effects in prostatic cancer cells with half maximal inhibitory concentratio... | |||
T17689 | Boc-Pip-alkyne-Ph-COOH | Others | |
Boc-Pip-alkyne-Ph-COOH, a PROTAC linker characterized by its alkyl/ether composition, plays a crucial role in synthesizing PROTACs including ARD-266. This compound demonstrates significant efficacy in promoting the degra... | |||
T74410 | PROTAC AR-V7 degrader-1 | ||
PROTAC AR-V7 degrader-1 (Compound 6) is an orally bioavailable, potent, and selective degrader targeting the androgen receptor (AR) variant V7, achieving degradation with a DC50 of 0.32 µM by directing the VHL E3 ligase ... | |||
T83853 | L-K6L9 TFA | ||
L-K6L9, a cytolytic peptide comprised of L-isomer leucine and lysine, demonstrates cytotoxicity against both androgen-independent (LNCaP-CL1) and androgen-dependent (22Rv1 and LNCaP) human prostate cancer cells, with LC5... | |||
T83936 | LL-K9-3 | ||
LL-K9-3, a selective hydrophobic tagging technology (HyT)-based degrader, specifically targets the CDK9-cyclin T1 complex, displaying DC50 values of 589 nM for cyclin T1 and 662 nM for CDK9. This compound consists of the... | |||
T30123 | ARD-69 | ||
ARD-69 is a Highly Potent Proteolysis Targeting Chimera (PROTAC) Degrader of Androgen Receptor (AR) for the Treatment of Prostate Cancer. ARD-69 induces degradation of AR protein in AR-positive prostate cancer cell lines... |